Bone mineral and calcium metabolism before, during and after treatment of osteoporosis with 1 alpha-hydroxyvitamin D3 and calcium
- PMID: 7063813
- DOI: 10.3109/03009748209098116
Bone mineral and calcium metabolism before, during and after treatment of osteoporosis with 1 alpha-hydroxyvitamin D3 and calcium
Abstract
A series of osteoporotic patients treated for 25 months (average) with 1 alpha-hydroxyvitamin D3 (1 alpha-OHD3) supplemented with calcium were examined in respect of calcium metabolism and bone mineral changes before, during, and 12 months after cessation of treatment. The bone mineral content, which increased during treatment, showed a decreasing post-treatment tendency. The decrease was more obvious in patients with senile osteoporosis. The levels of serum calcium and phosphate stayed within normal levels. The urinary calcium excretion rate, which also rose during treatment, returned to pre-treatment values after discontinuing treatment. Excretion of urinary phosphate, however, showed a tendency towards further decrease. Serum PTH stayed within normal levels, while serum alkaline phosphatase, which was depressed during treatment, rose again after treatment. The investigation speaks in favour of a continuous administration of 1 alpha-OHD3 and calcium which is generally noted to increase bone mineral during long-term treatment.
Similar articles
-
Results of long-term treatment of osteoporosis with 1 alpha-hydroxyvitamin D3 and calcium.Ital J Orthop Traumatol. 1984 Jun;10(2):187-201. Ital J Orthop Traumatol. 1984. PMID: 6432736 Clinical Trial.
-
Short-term effects of varying doses of 1 alpha-hydroxyvitamin D3 on blood and urine chemistry and calcium absorption of osteoporotic patients.Clin Orthop Relat Res. 1978 Sep;(135):226-31. Clin Orthop Relat Res. 1978. PMID: 709935
-
Preventive treatment of osteoporosis with 1 alpha-hydroxyvitamin D3 and calcium. Evaluation of bone histomorphometry in osteoporotics and age matched controls.Acta Vitaminol Enzymol. 1982;4(1-2):179-84. Acta Vitaminol Enzymol. 1982. PMID: 7124565 No abstract available.
-
1-alpha-Hydroxyvitamin D3 derivatives in the treatment of renal bone diseases: justification and optimal modalities of administration.Nephron. 1995;71(3):254-83. doi: 10.1159/000188732. Nephron. 1995. PMID: 8569975 Review.
-
Renal osteodystrophy in dialysis patients: diagnosis and treatment.Artif Organs. 1998 Jul;22(7):530-57. doi: 10.1046/j.1525-1594.1998.06198.x. Artif Organs. 1998. PMID: 9684690 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical